

ABSTRACT

5 A therapeutic agent for myeloma comprising a
combined use of a nitrogen mustard anticancer agent and
anti-IL-6 receptor antibody. Thus, a therapeutic agent
for myeloma comprising anti-IL-6 receptor antibody for
use in combination with a nitrogen mustard anticancer
agent; a therapeutic agent for myeloma comprising a
nitrogen mustard anticancer agent for use in combination
10 with anti-IL-6 receptor antibody; and a therapeutic agent
for myeloma comprising a nitrogen mustard anticancer
agent and anti-IL-6 receptor antibody.